SAT0088 Hdl cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis

Abstract Background: Poor cholesterol efflux capacity (CEC) has been proposed to be an independent risk factor for cardiovascular diseases. However, the current evidences in the literature are inconsistent. This meta-analysis aimed to identify whether CEC is impaired or altered by drug therapy in individuals with rheumatoid arthritis (RA).Methods: The PubMed, Embase, and Cochrane library databases were searched to identify studies on CEC in RA patients. The searches were focused on studies in human subjects that were published before 10 June 2020, without language restrictions. The primary outcomes were CEC and the high-density lipoprotein cholesterol (HDL-C) and C-reactive protein levels (CRP) levels.Results: A total of 11 eligible articles, including 6 observational and 5 intervention studies, were retrieved. The pooled results showed that CEC is not significantly lower in RA patients than in healthy controls (SMD: -0.22, 95% CI: -0.65 to 0.20), whereas the plasma HDL-C level is not significantly (WMD: -3.98, 95% CI: -8.32 to 0.37, I² = 54%, P for heterogeneity = 0.050) but is significantly decreased in the RA patients with moderate body mass index (BMI) (WMD: -5.46, 95% CI: -9.40 to -1.52, I² = 37%, P for heterogeneity = 0.175). Furthermore, in the before-after studies, the CEC of RA patients (SMD: 0.20, 95% CI: 0.03 to 0.38) increased, but the plasma HDL-C level (WMD: 3.26, 95% CI: -0.17 to 6.69) remained at a similar level after anti-rheumatic treatment compared to the baseline. In addition, stratified analysis suggested that the Disease Activity Score for 28 joints could be a potential source of heterogeneity for CEC. The funnel plot was relatively symmetric and did not suggest the presence of publication bias.Conclusion：The current meta-analysis demonstrated that HDL-mediated CEC can be improved by the early control of inflammation and anti-rheumatic treatment in RA patients, which is independent of HDL-C levels. Future research is needed to determine whether therapeutic strategies to enhance CEC in RA patients have beneficial effects for preventing CVD.

Download Full-text

High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with low HDL-cholesterol and subclinical atherosclerosis

BBA Clinical ◽

10.1016/j.bbacli.2015.05.039 ◽

2015 ◽

Vol 3 ◽

pp. S13-S14

Author(s):

Jose Carlos Lima ◽

Natalia B. Panzoldo ◽

Eliane S. Parra ◽

Vanessa H.S. Zago ◽

Isabela C. Vieira ◽

...

Keyword(s):

High Density Lipoprotein ◽

Cholesterol Efflux ◽

Subclinical Atherosclerosis ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

High Density ◽

Phospholipid Content ◽

Cholesterol Efflux Capacity ◽

Low Hdl

Download Full-text

Differences in HDL‐Cholesterol Efflux Capacity Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Arthritis Care & Research ◽

10.1002/acr.24407 ◽

2020 ◽

Author(s):

Juan C. Quevedo‐Abeledo ◽

Hiurma Sánchez‐Pérez ◽

Beatriz Tejera‐Segura ◽

Laura de Armas‐Rillo ◽

Estefanía Armas‐González ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Cholesterol Efflux ◽

Hdl Cholesterol ◽

Systemic Lupus ◽

Cholesterol Efflux Capacity

Download Full-text

The Association Between Reduction in Inflammation and Changes in Lipoprotein Levels and HDL Cholesterol Efflux Capacity in Rheumatoid Arthritis

Journal of the American Heart Association ◽

10.1161/jaha.114.001588 ◽

2015 ◽

Vol 4 (2) ◽

Cited By ~ 55

Author(s):

Katherine P. Liao ◽

Martin P. Playford ◽

Michelle Frits ◽

Jonathan S. Coblyn ◽

Christine Iannaccone ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cholesterol Efflux ◽

Hdl Cholesterol ◽

Cholesterol Efflux Capacity

Download Full-text

A Meta-Analysis of HDL Cholesterol Efflux Capacity and Concentration in Patients With Rheumatoid Arthritis

10.21203/rs.3.rs-97452/v1 ◽

2020 ◽

Author(s):

Binbin Xie ◽

Jiang He ◽

Yong Liu ◽

Ting Liu ◽

Chaoqun Liu

Keyword(s):

Rheumatoid Arthritis ◽

Cholesterol Efflux ◽

Human Subjects ◽

Meta Analysis ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Cochrane Library ◽

Future Research ◽

Cholesterol Efflux Capacity ◽

Beneficial Effects

Abstract Background: Poor cholesterol efflux capacity (CEC) has been proposed to be an independent risk factor for cardiovascular diseases. However, the current evidences in the literature are inconsistent. This meta-analysis aimed to identify whether CEC is impaired or altered by drug therapy in individuals with rheumatoid arthritis (RA).Methods: The PubMed, Embase, and Cochrane library databases were searched to identify studies on CEC in RA patients. The searches were focused on studies in human subjects that were published before 10 Sep 2020, without language restrictions. The primary outcomes were CEC and the high-density lipoprotein cholesterol (HDL-C) and C-reactive protein levels (CRP).Results: A total of 11 eligible articles, including 6 observational and 5 intervention studies, were retrieved. The pooled results showed that CEC is not significantly lower in RA patients than in healthy controls (SMD: -0.34, 95% CI: -0.83 to 0.14), whereas the plasma HDL-C level is not significantly lower HDL-C levels (WMD: -3.91, 95% CI: -7.15 to -0.68). Furthermore, in the before-after studies, the CEC of RA patients (SMD: 0.20, 95% CI: 0.02 to 0.37) increased, but the plasma HDL-C level (WMD: 3.63, 95% CI: -0.13 to 7.39) remained at a similar level after anti-rheumatic treatment compared to the baseline. In addition, the funnel plot was relatively symmetric and did not suggest the presence of publication bias.Conclusion: The current meta-analysis demonstrated that HDL-mediated CEC can be improved by the early control of inflammation and anti-rheumatic treatment in RA patients, which is independent of HDL-C levels. Future research is needed to determine whether therapeutic strategies to enhance CEC in RA patients have beneficial effects for preventing CVD.

Download Full-text

Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis

Scientific Reports ◽

10.1038/s41598-018-29639-5 ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 13

Author(s):

Reza Fadaei ◽

Hossein Poustchi ◽

Reza Meshkani ◽

Nariman Moradi ◽

Taghi Golmohammadi ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Cholesterol Efflux ◽

Subclinical Atherosclerosis ◽

Hdl Cholesterol ◽

Alcoholic Fatty Liver ◽

Cholesterol Efflux Capacity ◽

Alcoholic Fatty Liver Disease

Download Full-text

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Cells ◽

10.3390/cells10030574 ◽

2021 ◽

Vol 10 (3) ◽

pp. 574

Author(s):

Maria Pia Adorni ◽

Nicoletta Ronda ◽

Franco Bernini ◽

Francesca Zimetti

Keyword(s):

High Density Lipoprotein ◽

Cholesterol Efflux ◽

Current Knowledge ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

High Density ◽

Current Evidence ◽

Endocrine Disorders ◽

Lifestyle Modifications ◽

Cholesterol Efflux Capacity

Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.

Download Full-text

Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus

International Journal of Molecular Sciences ◽

10.3390/ijms20030732 ◽

2019 ◽

Vol 20 (3) ◽

pp. 732 ◽

Cited By ~ 4

Author(s):

Robin Dullaart ◽

Sabrina Pagano ◽

Frank Perton ◽

Nicolas Vuilleumier

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Apolipoprotein B ◽

Cholesterol Efflux ◽

Hdl Cholesterol ◽

Enzyme Linked Immunosorbent Assay ◽

Cholesterol Efflux Capacity ◽

C Terminus

Background: We determined relationships of cholesterol efflux capacity (CEC), plasma cholesterol esterification (EST) and cholesteryl ester transfer (CET) with anti-c-terminus apoA-1 (Ac-terAA1) and anti-apolipoprotein (apo)-1 (AAA1) autoantibodies in subjects with and without Type 2 diabetes mellitus (T2D). Methods: In 75 T2D subjects and 75 nondiabetic subjects, Ac-terAA1 and AAA1 plasma levels were measured by enzyme-linked immunosorbent assay. CEC was measured as [3H]-cholesterol efflux from human cultured fibroblasts to diluted individual subject plasma. Plasma EST and CET were assayed by isotope methods. Results: Ac-terAA1 and AAA1 levels and were similar between T2D and control subjects. Univariate regression analysis (n = 150) demonstrated that Ac-terAA1 levels were inversely correlated with CEC, EST, CET, total cholesterol, non-HDL cholesterol, triglycerides and apolipoprotein B, (p < 0.05 to p < 0.01), but not with glucose and HbA1c. In separate multivariable linear regression models, CEC, EST and CET were inversely associated with Ac-terAA1 levels independently of age, sex, T2D and drug use (β = −0.186, p = 0.026; β = −0.261, p < 0.001; and β = −0.321, p < 0.001; respectively). These associations were lost after additional adjustment for non-HDL cholesterol and triglycerides. No associations were observed for AAA1. Conclusions: CEC, plasma EST and CET are inversely associated with Ac-terAA1 autoantibodies, conceivably attributable to an inverse relationship of these autoantibodies with apolipoprotein B-containing lipoproteins.

Download Full-text